RNAi modulation of RSV and therapeutic uses thereof

Details for Australian Patent Application No. 2006203934 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Meyers, Rachel

Agent FB Rice

Pub. Number AU-B-2006203934

PCT Pub. Number WO2006/074346

Priority 60/659,828 09.03.05 US; 60/642,364 07.01.05 US

Filing date 6 January 2006

Wipo publication date 13 July 2006

Acceptance publication date 9 September 2010

International Classifications

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

A61K 31/70 (2006.01) - Carbohydrates

Event Publications

19 July 2007 PCT application entered the National Phase

  PCT publication WO2006/074346 Priority application(s): WO2006/074346

9 September 2010 Application Accepted

  Published as AU-B-2006203934

13 January 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006203946-Compositions and methods relating to novel compounds and targets thereof

2006203931-Engineered adsorbent structures for kinetic separation